

State of Oklahoma SoonerCare



Nivestym[®] (Filgrastim-aafi), Neulasta[®] (Pegfilgrastim), Releuko[™] (Filgrastim-ayow), Stimufend[®] (Pegfilgrastim-fpgk), Udenyca[®] (Pegfilgrastim-cbqv), Nyvepria[™] (pegfilgrastim-pbbk) and Rolvedon[™] (Eflapegrastim-xnst) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
Physician billing (HCPCS code:)	nacy billing (NDC:)
Dose:Dosing Regimen:		Start Date (or date of next dose):
Expected Treatment Duration/Number of Doses:		
Billing Provider Information		
Provider NPI:	Provider Name:	
Provider Phone:	Provide	er Fax:
Prescriber Information		
Prescriber NPI:	Prescriber Name	:
Prescriber Phone: Pr	rescriber Fax:	Specialty:
Criteria		
sis and information: A. Diagnosis: B. Please provide a patient-sp Fulphila® (pegfilgrastim-jmd	ecific, clinically sign	apegrastim-xnst), please indicate the diagno- ifficant reason why the member cannot use Igrastim-pbbk 6mg/0.6ml), Granix [®] (tbo- grastim-sndz), or Ziextenzo [®] (pegfilgrastim-
 2. For Nivestym[®] (Filgrastim-aafi) and Releuko[™] (Filgrastim-ayow), please indicate the diagnosis and information: A. Diagnosis:		
Additional Information:		
Prescriber Signature: I certify that the indicated treatment the best of my knowledge.	is medically neces	Date:sary and all information is true and correct to

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at

AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 208 7/19/2023